Report of Foreign Issuer (6-k)
19 March 2019 - 12:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 18, 2019
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk settles US patent litigation case on Victoza®
(liraglutide) with Teva
Bagsværd, Denmark, 18 March 2019
-
Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been
reached on the US patent litigation case for Victoza
®
(liraglutide). Consequently, Teva
is licensed to launch a generic version of Victoza
®
as of 22 December 2023.
Under certain circumstances Teva could launch
a generic version of Victoza
®
earlier, but not before 22 March 2023, unless the Victoza
®
patents are no longer in force or there is another generic version of Victoza
®
on
the market. If Novo Nordisk is granted six months paediatric extension for Victoza
®
, all
above-mentioned timelines will be extended by six months. All other terms of the agreement are confidential.
The agreement is subject to review by the US
Federal Trade Commission and the US Department of Justice.
“This settlement reflects the comprehensive
US patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative
drugs against challenges,” said Jesper Brandgaard, executive vice president and head of Biopharm and Legal Affairs of Novo
Nordisk.
Novo
Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has
given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets
its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are
listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Page 2 of 2
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 4442 3883
|
mkd@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 16 / 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: March 18, 2019
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024